ADORA2A and COVID-19: Furthermore, as discussed in the introduction, since α2 AR agonists may share overlap in function as an immunomodulator as compared to α1 AR antagonists, insights from the clinical trial investigating an α1 AR antagonist in the potential to reduce COVID-19 mortality (NCT04365257) may be applicable.